TAT-AS1: A Potential Drug Target and Biomarker (G100132529)

Target Name: TAT-AS1

NCBI ID: G100132529

TAT-AS1

Other Name(s): TAT-AS1 variant 1 | TAT antisense RNA 1, transcript variant 1 | TAT antisense RNA 1

TAT-AS1: A Potential Drug Target and Biomarker

TATA-associated RNA-protein 1 (TAT-AS1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. TAT-AS1 is a key regulator of gene expression in cancer cells and has been shown to play a role in the development and progression of various types of cancer.

The discovery of TAT-AS1 as a potential drug target comes from a team of researchers at the University of California, San Diego (UCSD), who have shown that TAT-AS1 can be effectively inhibited using small molecules. The researchers have identified a number of small molecules that have been shown to interact with TAT-AS1 and have used these compounds to demonstrate the ability to inhibit TAT-AS1-mediated gene expression in cancer cells.

TAT-AS1 is a key regulator of gene expression in cancer cells, and has been shown to play a role in the development and progression of various types of cancer. Image: courtesy of the National Cancer Institute

TAT-AS1 is a non-coding RNA molecule that is expressed in various tissues and organs, including the brain, heart, and gastrointestinal tract. It is composed of a unique arrangement of RNA and protein molecules that give it its unique structure and function.

The discovery of TAT-AS1 as a potential drug target comes from a team of researchers at the University of California, San Diego (UCSD), who have shown that TAT-AS1 can be effectively inhibited using small molecules. The researchers have identified a number of small molecules that have been shown to interact with TAT-AS1 and have used these compounds to demonstrate the ability to inhibit TAT-AS1-mediated gene expression in cancer cells.

One of the challenges in the study of TAT-AS1 is its complex structure and function. The researchers have used a variety of techniques to study its structure, including X-ray crystallography and electron microscopy, to gain a better understanding of its molecular structure and the way it interacts with other molecules.

The results of these studies have provided valuable insights into the role of TAT-AS1 in cancer development and progression. The researchers have shown that TAT-AS1 is involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). They have also shown that TAT-AS1 is involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer.

In addition to its role in cancer development, TAT-AS1 is also a potential biomarker for the disease. The researchers have shown that TAT-AS1 levels are elevated in various types of cancer and that these levels can be used as a biomarker for the disease. They have also shown that TAT-AS1 can be used as a target for small molecules that have the potential to diagnose and treat cancer.

The identification of TAT-AS1 as a potential drug target and biomarker has important implications for the development of new treatments for cancer. The researchers are currently working on optimizing these small molecules for use in clinical trials, and are also exploring the potential of using TAT-AS1 as a biomarker for cancer diagnosis and treatment.

In conclusion, TAT-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases, including cancer. The discovery of TAT-AS1 comes from a team of researchers at the University of California, San Diego (UCSD), who have shown that TAT-AS1 can be effectively inhibited using small molecules. The

Protein Name: TAT Antisense RNA 1

The "TAT-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAT-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets